The purpose of the study is to evaluate the safety and tolerability of this therapy during the first weeks after it is given. Participants receive a single infusion and remain under close observation for about four weeks, with additional check‑ups extending to day 42 if low blood cell counts (cytopenias) persist. After the initial monitoring period, follow‑up visits continue for several months to watch for any delayed effects.

Safety assessments include regular blood tests to check for changes in cell counts, kidney function tests to see how well the kidneys are working, and physical examinations. If any side effects appear, they are treated promptly according to standard medical practice.

The purpose of the study is to evaluate the long-term safety of KYV-101. Participants will be monitored over an extended period to observe how the body reacts to the medication over time. This involves checking for the development of new health issues, such as malignancy, which refers to cancerous growths, or any changes in existing neurologic conditions, which are related to the brain and nervous system. The study also tracks changes in rheumatologic issues, which involve the joints and connective tissues, or hematologic disorders, which are conditions affecting the blood.

Patients participating in this study will be randomly assigned to receive either the three-medication combination or the two-medication combination. During the study, patients will undergo kidney biopsies, which are procedures where a small sample of kidney tissue is taken using a needle, to examine the level of inflammation and the presence of certain immune cells called macrophages in the kidney. These biopsies will be performed at the beginning of the study and again after three months of treatment. The study will also collect blood and urine samples to look for markers that might help doctors understand how well the treatment is working without needing to perform repeat kidney biopsies in the future. The study will follow patients for up to two years to see if early improvements in kidney inflammation are connected to long-term kidney health.

The study will also include two comparison groups: one group of patients with systemic lupus erythematosus who do not have kidney involvement, and one group of healthy individuals without any disease. These groups will help researchers better understand the differences in immune cell patterns between people with lupus nephritis, those with lupus without kidney problems, and healthy individuals. The information gathered from all participants will be used to identify potential new ways to monitor disease activity and treatment response that could make future care easier and less invasive for patients with lupus nephritis.

The purpose of this study is to evaluate how well obecabtagene autoleucel works and how safe it is for people with severe lupus that has not responded well to other treatments and who have active kidney involvement. The study will measure whether the treatment can help improve kidney function by looking at protein levels in urine and the rate at which the kidneys filter blood, and whether these improvements can be achieved without needing additional rescue treatments.

During the study, participants will first undergo a screening process to determine if they are suitable. If eligible, they will have their T cells collected through a process where blood is drawn from the body, the needed cells are separated, and the remaining blood is returned. These cells are then sent to a facility where they are modified and grown. Before receiving the modified cells back through an infusion into a vein, participants will receive the two preparatory medications over several days. After the infusion of the modified cells, participants will be monitored closely for side effects and will have regular follow-up visits for up to two years. Throughout this time, various tests will be performed to check kidney function, measure disease activity, assess quality of life, monitor for side effects, and track how long the modified cells remain in the body and how they affect the immune system.

Before receiving the main treatment, patients will undergo preparation with three medications: cyclophosphamide, fludarabine, and tocilizumab. These medications are given through intravenous infusion to prepare the body for the CAR T cell treatment. The purpose of this study is to evaluate how effective CC-97540 is in treating patients with SLE who haven’t responded well enough to previous treatments with steroids and other immune-suppressing medications.

The treatment process involves collecting the patient’s own immune cells, modifying them in a laboratory to target specific disease-causing cells, and then returning them to the patient through an intravenous infusion. After the treatment, patients will be monitored to see if their disease symptoms improve and if they can achieve remission without needing other medications.

Participants in this study will receive ianalumab through a solution for injection. The study will observe the participants over a period to see if there are any changes in their condition, such as a return of kidney problems or the need to increase other medications that suppress the immune system. The study will also monitor for any side effects or health changes that may occur during the treatment period.

In addition to ianalumab, the study involves other medications that participants may have been taking, such as mycophenolate mofetil, tenofovir alafenamide, emtricitabine, tenofovir disoproxil, and entecavir. These medications are typically used to manage immune system activity and viral infections. The study will help determine the best approach to managing lupus nephritis in the long term, either by continuing the treatment or by safely withdrawing it.

The purpose of the study is to evaluate how well ianalumab works in combination with standard-of-care therapy, which is the usual treatment given for lupus nephritis. Participants in the study will receive either ianalumab or a placebo, along with their regular treatment. The study will last for a period of time, during which participants will have regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, researchers will look at various outcomes, such as the stability of kidney function and any side effects that may occur. The goal is to see if ianalumab can help achieve a stable and complete response in kidney function by the end of the study period. Participants will be closely monitored to ensure their safety and to gather important information about the treatment’s effectiveness and tolerability.

Participants in the study will receive either Obinutuzumab or a placebo. The study will last for about 76 weeks, during which time participants will have regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to see if the treatment can help achieve a complete or partial improvement in kidney function and reduce symptoms of the disease. The study will also track any side effects or changes in health that occur during the treatment period.

In addition to Obinutuzumab, the study involves other medications like Myfenax and CellCept, which contain the active ingredient Mycophenolate Mofetil. These medications are used to suppress the immune system and help manage symptoms of Lupus Nephritis. The study will help determine the best way to use these treatments to improve the health of patients with this condition. Participants will be closely monitored to ensure their safety and to gather important information about how these treatments work in young patients.

Participants in the study will receive either rapcabtagene autoleucel or one of the standard treatments, which may include medications like cyclophosphamide, voclosporin, belimumab, rituximab, mycophenolate mofetil, tacrolimus, or fludarabine phosphate. Rapcabtagene autoleucel is a type of cell therapy that involves modifying a person’s own immune cells to better fight the disease. The study will last for about a year, during which participants will be monitored to see how well the treatment works and to check for any side effects.

The study is designed to help researchers understand if rapcabtagene autoleucel can provide better outcomes for patients with lupus nephritis compared to the current standard treatments. Participants will be assessed for improvements in their condition and any changes in their health over the course of the study. This research aims to find more effective ways to manage and treat lupus nephritis, potentially offering new hope for those affected by this challenging condition.

The purpose of this research is to determine if treating patients with obinutuzumab and MMF without additional oral corticosteroids works as well as the traditional treatment using corticosteroids and MMF. The study measures how well the kidneys respond to treatment after 52 weeks. During the treatment period, patients receive their assigned medications according to a specific schedule. Obinutuzumab is given through an intravenous infusion, while MMF is taken as oral tablets.

Throughout the study, doctors monitor kidney function by checking protein levels in urine and measuring how well the kidneys filter blood. They also track any side effects that may occur during treatment. Some patients may also receive other medications like azathioprine or prednisolone as part of their treatment plan.

Participants in the study will receive either the MSV-allo treatment or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. The study will last for several months, with regular check-ups to monitor the participants’ health and any changes in their condition. The main goal is to see how many patients experience improvement in their lupus nephritis symptoms by the end of the study period.

Throughout the study, researchers will also observe any changes in the use of medications like corticosteroids, which are often used to manage lupus nephritis. They will track whether participants can reduce their medication doses without worsening their condition. The study aims to provide valuable information on whether MSV-allo can be a safe and effective treatment option for people with lupus nephritis.

Participants in the study will receive either Ravulizumab or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of time, during which participants will be monitored to see how their condition responds to the treatment. The main focus will be on changes in protein levels in the urine, which is a key indicator of kidney health. Other aspects of kidney function and overall health will also be assessed.

This study is designed to help understand whether Ravulizumab can improve the health of people with Lupus Nephritis or Immunoglobulin A Nephropathy. By comparing the effects of the medication to a placebo, researchers aim to gather important information that could lead to better treatment options for these kidney diseases in the future.

The purpose of the study is to determine how well Anifrolumab works in helping patients achieve a complete renal response, which means improving kidney function and reducing inflammation. The study will involve regular visits to the clinic for infusions and monitoring over a period of time. Participants will be closely observed to ensure their safety and to track any changes in their condition.

Throughout the study, participants will receive standard care for their condition in addition to the study treatment. The goal is to see if adding Anifrolumab to the usual care can provide better outcomes for patients with Active Proliferative Lupus Nephritis. The study will help researchers understand if this treatment can be a beneficial option for managing this challenging condition.

Participants in the study will be randomly assigned to receive either the ALXN 2050 tablets or placebo tablets. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, during which participants will be monitored for changes in their condition and any side effects they may experience.

The trial aims to find the most effective dose of ALXN 2050 for treating these kidney diseases. Participants will have regular check-ups to assess their kidney function and overall health. The study will also look at how the medication affects the body and its safety. The ultimate goal is to determine if ALXN 2050 can be a beneficial treatment option for people with Lupus Nephritis or Immunoglobulin A Nephropathy.

The purpose of the study is to assess the safety of YTB323 in patients with srSLE. Participants will receive the treatment through an infusion, which means it is delivered directly into the bloodstream. The study will monitor how the treatment affects the body over time, including any side effects and how the immune cells behave after being modified. The study will also look at how well the treatment works in reducing the symptoms of srSLE.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. This includes checking vital signs, conducting blood tests, and evaluating any changes in the disease. The study aims to provide valuable information on the potential benefits and risks of using YTB323 for treating severe cases of SLE that have not responded to other treatments.

The purpose of the study is to evaluate how effective and safe the treatment is for patients with active lupus nephritis, specifically those with Class III-IV, with or without Class V. Participants will receive different doses of iptacopan, either with or without corticosteroids, alongside their standard treatment. The study will last for up to 52 weeks, with the main focus on the first 24 weeks to see how many patients achieve a complete renal response, meaning their kidney function improves without any worsening of their condition.

Throughout the study, participants will be monitored for any changes in their condition and any side effects they may experience. The trial aims to provide valuable information on whether iptacopan can be a beneficial addition to the current treatment options for lupus nephritis. This research could potentially lead to better management of the disease and improved outcomes for patients in the future.

Participants in the study will receive either Zetomipzomib or a placebo, which is a substance with no active medication. The study will compare the outcomes of those receiving Zetomipzomib to those receiving the placebo. The treatment will be administered as a subcutaneous injection, which means it is injected under the skin. The study will last for about a year, during which participants will have regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, the main goal is to see how many patients achieve a complete renal response, which means their kidney function improves significantly. The study will also look at other outcomes, such as partial renal response and changes in disease activity. This research aims to provide new insights into treating Lupus Nephritis and potentially offer a new treatment option for patients with this condition.